Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res. 2009 Jan 15; 15(2):578-88.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.